Ongoing clinical trials for allergic conjunctivitis (AC).
| Trial ID | Phase/Patients number | Aim | Strategy | Status/Results |
|---|---|---|---|---|
| NCT07273747 | N/A72 | To test whether oral Kelulut honey is safe and more effective than a honey-flavored placebo at improving AC symptoms. | One-month, parallel-group, placebo-controlled supplementation trial where adults with AC are assigned to take oral Kelulut honey or a honey-flavoured placebo, and outcomes are compared from baseline to 1 month. | Recruiting patients. |
| NCT01743027 | Phase III902 | To determine whether olopatidine (0.77%, 0.2%, 0.1%) is safe and provides relief of ocular itching in AC with rapid onset and 24-hour duration. | Multicenter, randomized, double-masked, phase 3 conjunctival allergen challenge (CAC) model where adults receive a single dose in both eyes and post-CAC itching scores at minutes 3/5/7, and 24 hours are measured. | Completed.Olopatadine 0.77% showed a rapid onset and sustained superiority in reducing ocular itching vs. vehicle and lower-dose olopatadine, with a favorable safety profile. |
| NCT07220408 | Phase II60 | To evaluate the safety/efficacy of TL-925 ophthalmic emulsion 0.1% vs. vehicle for treating seasonal AC in the CAC model. | Single-center, randomized, double-masked, vehicle-controlled phase 2 study assigning participants to either bilateral TL-925 vs. vehicle eye drops, then comparing post-challenge outcomes. | Recruiting patients. |
| NCT03186755 | Phase IV42 | To compare whether Hylo-Dual (hyaluronic acid 0.05% + ectoine 2.0%) is as effective as olopatadine 0.1% at controlling seasonal AC in children. | Phase 4, randomized, parallel, double-masked trial assigning 8 weeks of bilateral drops (Hylo-Dual TID vs. Patanol BID), then comparing clinical outcomes. | Recruiting patients. |
| NCT04207736 | Phase III95 | To test whether reproxalap ophthalmic solution 0.25% is effective and safe vs. vehicle for seasonal AC under controlled allergen exposure. | Single-center, randomized, double-masked, crossover, vehicle-controlled phase 3 study using an environmental exposure chamber (EEC) comparing outcomes after subjects received reproxalap vs. vehicle. | Completed.Reproxalap was statistically superior to vehicle across AC symptoms in the chamber model, with favorable tolerability/safety reported. |